Finance entity

Bachem Holding AG

Company BCHMF

Every one of those 1 sits in a single category, earnings. Eli Lilly is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.2 for that window.

Last mentioned: Mar 11, 2026

Entity pulse

Recent coverage · Bachem Holding AG

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Bachem Holding AG

Every one of those 1 sits in a single category, earnings. Eli Lilly is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.2 for that window. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. Bachem Holding AG appears in 1 tracked Finance story from March 11, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 89 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Bachem Holding AG. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Earnings Release

    Scheduled release of quarterly and full-year financial results for Bachem (BCHMF).

  2. Order Book Milestone

    Company reported record order intake driven by metabolic disease therapy demand.

  3. Capacity Expansion Phase

    Bachem announced a major investment in 'Building T' at its Bubendorf facility.

Stories mentioning Bachem Holding AG 1

Earnings Neutral

Bachem Earnings Preview: Peptide Demand and Capacity Expansion in Focus

Bachem (BCHMF) is set to report its quarterly financial results this Thursday, with investors closely monitoring the company's ability to scale production for the surging GLP-1 market. The Swiss peptide specialist remains a critical infrastructure provider for the global pharmaceutical industry's most profitable drug classes.

2 sources

Bachem Holding AG is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.